Fortress Biotech Files 8-K
Ticker: FBIOP · Form: 8-K · Filed: Jul 5, 2024 · CIK: 1429260
Sentiment: neutral
Topics: sec-filing, 8-k, routine-filing
Related Tickers: FBIO
TL;DR
FBIO filed an 8-K on 7/5/24, looks like routine stuff.
AI Summary
On July 5, 2024, Fortress Biotech, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific new financial figures or material events were detailed in the provided text, suggesting it may be a routine filing or related to previously disclosed information.
Why It Matters
This filing indicates Fortress Biotech is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural update without new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Fortress Biotech, Inc. (company) — Registrant
- 0001558370-24-009677 (filing_id) — Accession Number
- July 5, 2024 (date) — Report Date
- Delaware (jurisdiction) — State of Incorporation
- 1111 Kane Concourse, Suite 301 (address) — Principal Executive Offices
- Bay Harbor Islands, FL 33154 (address) — Principal Executive Offices Location
FAQ
What specific "Other Events" are being reported by Fortress Biotech on July 5, 2024?
The provided text for the 8-K filing lists "Other Events" as an item information, but does not specify the nature of these events.
Are there any new financial statements or exhibits being filed with this 8-K?
The filing lists "Financial Statements and Exhibits" as an item information, but the content of these exhibits is not detailed in the provided text.
What is the Central Index Key (CIK) for Fortress Biotech, Inc.?
The CIK for Fortress Biotech, Inc. is 0001429260.
When was Fortress Biotech, Inc. incorporated?
Fortress Biotech, Inc. is incorporated in Delaware.
What is the principal executive office address for Fortress Biotech, Inc.?
The principal executive office address is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-07-05 16:46:13
Key Financial Figures
- $0.1953125 — ecided to pause its monthly dividend of $0.1953125 per share of the Company's 9.375% Serie
- $0.7 million — hese dividends will defer approximately $0.7 million in cash dividend payments each month. T
Filing Documents
- fbio-20240705x8k.htm (8-K) — 38KB
- fbio-20240705xex99d1.htm (EX-99.1) — 14KB
- fbio-20240705xex99d1001.jpg (GRAPHIC) — 12KB
- 0001558370-24-009677.txt ( ) — 254KB
- fbio-20240705.xsd (EX-101.SCH) — 5KB
- fbio-20240705_def.xml (EX-101.DEF) — 15KB
- fbio-20240705_lab.xml (EX-101.LAB) — 13KB
- fbio-20240705_pre.xml (EX-101.PRE) — 15KB
- fbio-20240705x8k_htm.xml (XML) — 7KB
01. Other Events
Item 8.01. Other Events . On July 5, 2024, Fortress Biotech, Inc. (the " Company ") issued a press release announcing that its Board of Directors has decided to pause its monthly dividend of $0.1953125 per share of the Company's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the " Series A Preferred Stock "). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. In accordance with the terms of the Series A Preferred Stock, dividends on the Series A Preferred Stock will continue to accrue and cumulate until such dividends are authorized or declared. The pausing of these dividends will defer approximately $0.7 million in cash dividend payments each month. The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the pause should be lifted.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits . (d) Exhibits. The following exhibit is furnished herewith: 99 Exhibit Number Description 99.1 Press Release, dated July 5, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are imbedded in the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: July 5, 2024 By: /s/ Lindsay A. Rosenwald, M.D. Lindsay A. Rosenwald, M.D. Chairman, President and Chief Executive Officer